Loading…
Reported covered position: Legislative Assistant, Foreign Relations Committee
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Patent Reform Ace (S 515); Russian data exclusitivity; Saudi Zyprexa Patent nullification; Russia DE Enactment, Manager's Amendment to S 515; Counterfeit medicines
Follow-on biologics (HR 1548, HR 1427, S 726), Patent Reform (HR 1260, S 515, S 615), China IPR, Thailand IPR, Global Intellectual Property Rights and Anti-Counterfeiting
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · second_quarter · 2A
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership; Trans-Pacific Partnership
Anti-counterfeiting; Patient safety; Drug pedigree, serialization and traceability issues; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act; Promoting Public-Private Partnerships
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Source: Senate LDA
Patent Reform (S 515 & HR 1260); Finland (IP); Norway (IP & market access); Slovakia (IP & market access); China (counterfeiting); Global Anti-Counterfeiting, Anti-Counterfeiting Trade Agreement; World Health Organization; Canada (IP & market access); Mexico (IP & market access); Brazil (IP & market access); Algeria (IP & market access); Tunisia (IP & market access); Egypt (IP); Saudia Arabia (IP & market access); Argentina (IP & market access); Chili (IP); (CONTINUED NEXT PAGE) Turkey (IP & market access); Russia (IP & WTO accession); Israel (IP); Columbia (IP); China (anti-counterfeiting); Taiwan (IP & pricing reform);
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Anti-counterfeiting and patient safety; Anti-counterfeiting Trade Agreement (ACT); US-ASEAN Summit; S 242; Peru counterfeits; Netherland counterfeits; UK counterfeits/Parallel trade; France counterfeits/Parallel trade; EU Parallel trade; Germany Parallel trade; Algeria intellectual property; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695)
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Follow-on biologics (HR 1548, HR 1427, S 726), Patent Reform (HR 1260, S 515, S 615), China IPR, Thailand IPR, Global Intellectual Property Rights and Anti-Counterfeiting
Anti-counterfeiting and patient safety; Anti-counterfeiting Trade Agreement (ACT); US-ASEAN Summit; S 242; Peru counterfeits; Netherland counterfeits; UK counterfeits/Parallel trade; France counterfeits/Parallel trade; EU Parallel trade; Germany Parallel trade; Algeria intellectual property; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695)
Follow-on biologics (HR 1548, HR 1427, S 726), Patent Reform (HR 1260, S 515, S 615), China IPR, Thailand IPR, Global Intellectual Property Rights and Anti-Counterfeiting
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
America's Affordable Health Choices Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Anti-counterfeiting and patient safety; Anti-counterfeiting Trade Agreement (ACT); US-ASEAN Summit; S 242; Peru counterfeits; Netherland counterfeits; UK counterfeits/Parallel trade; France counterfeits/Parallel trade; EU Parallel trade; Germany Parallel trade; Algeria intellectual property; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695)
American Recovery and Reinvestment Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
A bill to authorize the award of a Congressional gold medal to the Montford Point Marines of World War II.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Anti-counterfeiting and patient safety; Anti-counterfeiting Trade Agreement (ACT); US-ASEAN Summit; S 242; Peru counterfeits; Netherland counterfeits; UK counterfeits/Parallel trade; France counterfeits/Parallel trade; EU Parallel trade; Germany Parallel trade; Algeria intellectual property; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695)
Title I Education Funding Integrity Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Anti-counterfeiting; Anti-counterfeiting Trade Agreement (ACTA); Ambassadorial nominations for the UN, US_ASEAN Summit; Canada S. 242 and intellectual property (IP); Mexico IP; Peru FTA; Columbia FTA; Algeria access; UK pricing; Germany HC reform; Saudi Arabia access/IP; Cuba sanctions; Argentina access and IP; Poland WTO; Russia WTO; Turkey access; Brazil trade negotiations; Japan pricing and regulatory reform; China IPR; Korea pricing reform and FTA; Taiwan pricing reform; Agriculture Appropriations/Trade Provisions (HR 2997)
Title I Education Funding Integrity Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Anti-counterfeiting and patient safety; Anti-counterfeiting Trade Agreement (ACT); US-ASEAN Summit; S 242; Peru counterfeits; Netherland counterfeits; UK counterfeits/Parallel trade; France counterfeits/Parallel trade; EU Parallel trade; Germany Parallel trade; Algeria intellectual property; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695)
Title I Education Funding Integrity Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual Property (IP) issues related to China, ASEAN countries, and India; IPR and Ambassadorial nominations for the UN; S. 242; Canada IP; Mexico IP; Brazil IP; Algeria IP; Egypt IP; Saudi Arabia IP; Peru IP/FTA implementation; Ecuador IP; Argentina IP; Chili IP; Columbia IP; Russia IP/WTO Accession; Turkey IP; Finland IP; Norway IP; Slovenia IP; Sweden IP
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Patent Reform (S 515 & HR 1260); Finland (IP); Norway (IP & market access); Slovakia (IP & market access); China (counterfeiting); Global Anti-Counterfeiting, Anti-Counterfeiting Trade Agreement; World Health Organization; Canada (IP & market access); Mexico (IP & market access); Brazil (IP & market access); Algeria (IP & market access); Tunisia (IP & market access); Egypt (IP); Saudia Arabia (IP & market access); Argentina (IP & market access); Chili (IP); (CONTINUED NEXT PAGE) Turkey (IP & market access); Russia (IP & WTO accession); Israel (IP); Columbia (IP); China (anti-counterfeiting); Taiwan (IP & pricing reform);
Follow-on biologics (HR 1548, HR 1427, S 726), Patent Reform (HR 1260, S 515, S 615), China IPR, Thailand IPR, Global Intellectual Property Rights and Anti-Counterfeiting
A bill to provide additional personnel authorities for the Special Inspector General for Afghanistan Reconstruction.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Follow-on biologics (HR 1548, HR 1427, S 726), Patent Reform (HR 1260, S 515, S 615), China IPR, Thailand IPR, Global Intellectual Property Rights and Anti-Counterfeiting
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Anti-counterfeiting and patient safety; Anti-counterfeiting Trade Agreement (ACT); US-ASEAN Summit; S 242; Peru counterfeits; Netherland counterfeits; UK counterfeits/Parallel trade; France counterfeits/Parallel trade; EU Parallel trade; Germany Parallel trade; Algeria intellectual property; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695)
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Follow-on biologics (HR 1548, HR 1427, S 726), Patent Reform (HR 1260, S 515, S 615), China IPR, Thailand IPR, Global Intellectual Property Rights and Anti-Counterfeiting
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Physician Pathology Services Continuity Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Anti-counterfeiting; Anti-counterfeiting Trade Agreement (ACTA); Ambassadorial nominations for the UN, US_ASEAN Summit; Canada S. 242 and intellectual property (IP); Mexico IP; Peru FTA; Columbia FTA; Algeria access; UK pricing; Germany HC reform; Saudi Arabia access/IP; Cuba sanctions; Argentina access and IP; Poland WTO; Russia WTO; Turkey access; Brazil trade negotiations; Japan pricing and regulatory reform; China IPR; Korea pricing reform and FTA; Taiwan pricing reform; Agriculture Appropriations/Trade Provisions (HR 2997)
American Middle Class Tax (AMT) Relief Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Anti-counterfeiting and patient safety; Anti-counterfeiting Trade Agreement (ACT); US-ASEAN Summit; S 242; Peru counterfeits; Netherland counterfeits; UK counterfeits/Parallel trade; France counterfeits/Parallel trade; EU Parallel trade; Germany Parallel trade; Algeria intellectual property; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695)
Pharmaceutical Market Access and Drug Safety Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Veterinary Medicine Market Access; Czech Republic (market access & pricing reform); European Union (Pharmaceutical Package legislation); Finland (IP); Germany (pricing & health care reform); Italy (pricing & health care reform); Norway (IP & market access); Poland (market access); Slovakia (IP & market access); Sweden (pricing & health care reform); United Kingdon (pricing & health care reform); Anti-Counterfeiting Trade Agreement; Latin America Free Trade Agreements; (CONTINUED ON NEXT PAGE) Canada (Pharmaceutical Market Access and Drug Safety Act - S 242 & access restrictions & IP); Cuba (omnibus bill & sanctions); Mexico (IP & market access); Brazil (IP & market access); Algeria (IP & access restrictions); Tunisia (IP & access restrictions); Egypt (IP); Saudia Arabia (IP & access restrictions); Peru (FTA Implementation); Argentina (IP & access restrictions); Chili (IP); Turkey (IP & access restrictions); Russia (IP & WTO accession); Israel (IP); Columbia (IP); South Africa (access restrictions); Japan (pricing & regulatory reform); China (anti-counterfeiting & pricing reform); Taiwan (pricing reform & IP); Korea (pricing reform); Thailand (CL); Indonesia (investment decree); Philippines (pricing reform);
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · fourth_quarter · Q4
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership; Trans-Pacific Partnership
Anti-counterfeiting; Patient safety; Drug pedigree, serialization and traceability issues; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Promoting Public-Private Partnerships; UN High Level Panel on Access to Medicines (UNHLP) and Other Multi-lateral Threats to IP and the Biopharmaceutical Industry
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · second_quarter · 2A
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership; Trans-Pacific Partnership
Anti-counterfeiting; Patient safety; Drug pedigree, serialization and traceability issues; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act; Promoting Public-Private Partnerships
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · third_quarter · Q3
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership; Trans-Pacific Partnership
Anti-counterfeiting; Patient safety; Drug pedigree, serialization and traceability issues; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act; Promoting Public-Private Partnerships
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · second_quarter · Q2
Anti-counterfeiting; Patient safety; Drug pedigree, serialization and traceability issues; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act; Promoting Public-Private Partnerships
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership; Trans-Pacific Partnership
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · first_quarter · Q1
Anti-counterfeiting; Patient safety; Drug pedigree, serialization and traceability issues; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act; Promoting Public-Private Partnerships
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2015 · fourth_quarter · Q4
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership, TPP
Anti-counterfeiting; Patient safety; Drug pedigree, serialization and traceability issues; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act; Promoting Public-Private Partnerships
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2015 · third_quarter · Q3
Anti-counterfeiting; Patient safety; Drug pedigree, serialization and traceability issues; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act; Promoting Public-Private Partnerships
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership, TPP
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2015 · second_quarter · Q2
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership
Anti-counterfeiting; Patient safety; Drug pedigree provisions; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2015 · first_quarter · Q1
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership
Anti-counterfeiting; Patient safety; Drug pedigree provisions; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2014 · fourth_quarter · 4A
Anti-counterfeiting; Patient safety; Drug pedigree provisions; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Turkey Pricing; Russia pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership; Asia Pacific Economic Cooperation; China IPR
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2014 · fourth_quarter · Q4
Anti-counterfeiting; Patient safety; Drug pedigree provisions; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Turkey Pricing; Russia pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership; Asia Pacific Economic Cooperation; China IPR
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2014 · third_quarter · Q3
Anti-counterfeiting; Patient safety; Drug pedigree provisions; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership; Colombia biologics
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2014 · second_quarter · Q2
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership;
Anti-counterfeiting; Patient safety; Drug pedigree provisions; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2014 · first_quarter · Q1
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership;
Anti-counterfeiting; Patient safety; Drug pedigree provisions; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · fourth_quarter · Q4
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership;
Anti-counterfeiting; Patient safety; Drug pedigree provisions; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · third_quarter · Q3
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Russia PNTR; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent protection; CODEX; Portugal cost containment; Hungary cost containment; Canada IP; Poland market access; Greece price reform; Romania cost containment
Anti-counterfeiting; Patient safety; Drug pedigree provisions
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · second_quarter · Q2
Anti-counterfeiting; Patient safety; Drug pedigree provisions
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Russia PNTR; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent protection; CODEX; Portugal cost containment; Hungary cost containment; Canada IP; Poland market access; Greece price reform; Romania cost containment
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · second_quarter · Q2
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Russia PNTR; Turkey pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent Protection; CODEX; Portugal cost-containment; Hungary cost-containment; Canada IP; Poland market access; Greece price reform; Romania cost-containment
Anti-counterfeiting; Patent safety; Drug pedigree provisions
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · second_quarter · Q2
Anti-counterfeiting; Patient safety; Drug pedigree provisions;
Sanitary and Phytosanitary issues (SPS); TPP; Japan; KORUS; Russia PNTR; Turkey pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent Protection; CODEX; Portugal cost-containment; Hungary cost-containment; Canada IP; Poland market access; Greece price reform; Romania cost-containment
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · first_quarter · Q1
Anti-counterfeiting; Patient safety; Drug pedigree provisions;
Sanitary and Phytosanitary issues (SPS); TPP; Japan; KORUS; Russia PNTR; Turkey pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent Protection; CODEX; Portugal cost-containment; Hungary cost-containment; Canada IP; Poland market access; Greece price reform; Romania cost-containment
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2012 · fourth_quarter · Q4
Sanitary and Phytosanitary issues (SPS); TPP; Japan; KORUS; Russia PNTR; Turkey pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent Protection; CODEX; Portugal cost-containment; Hungary cost-containment; Canada IP; Poland market access; Greece price reform; Romania cost-containment
Anti-counterfeiting; Patient safety; Drug pedigree provisions;
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2012 · third_quarter · Q3
Anti-counterfeiting; Patient safety; Drug pedigree provisions;
Sanitary and Phytosanitary issues (SPS); TPP; Japan; KORUS; Russia PNTR; Turkey pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent Protection; CODEX; Portugal cost-containment; Hungary cost-containment; Canada IP; Poland market access; Greece price reform; Romania cost-containment
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2012 · second_quarter · Q2
Anti-counterfeiting; Patient safety
Sanitary and Phytosanitary issues (SPS); TPP, Japan; KORUS; Russia PNTR; Turkey pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent Protection
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2012 · first_quarter · Q1
Anti-counterfeiting; Patient Safety
SPS Issues; Veterinary Medicine; TPP; Russia PNTR; Turkey Pricing; IPR and Pricing; Germany Pricing Reforms; Poland Market Access; Greece Pricing Reform; Spain IP/Pricing
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2011 · fourth_quarter · Q4
TPP; Russia PNTR; Turkey Pricing; Veterinary Medicine - S/PS Issues; IPR and Pricing; Germany pricing reforms; Poland Market Access; Greece Pricing Reform; Spain IP/Pricing
Anti-counterfeitering; Patient Safety
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2011 · third_quarter · Q3
Patent reform; Anti-counterfeiting; Patient Safety
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2011 · second_quarter · Q2
America Invents Act (patent reform)(HR 1249); Anti-Counterfeiting; Patient safety
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2011 · first_quarter · Q1
Anti-counterfeiting/Patient Safety
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2010 · fourth_quarter · Q4
Russia DE; Saudi Zyprexa Issue; Mexico IP legislation; Trade issues (S/PS, EU, China, Russia, Korea, Vietnam); IP Issues; China IPR, US-Japan Trade Forum and Reform; KORUS and Krean Reform; Taiwan Reforms; Turkey GMP Inspection Requirement; Germany Pricing Reform; Poland Market Access; Greece Pricing Reform; Italy Market Access; Veterinary Medicine - S/PS Issues
Anti-counterfeiting/Patient Safety
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2010 · third_quarter · Q3
Anti-counterfeiting Patient Safety
Russia DE; Saudi Zyprexa Issue; Mexico IP legislation; Trade issues (S/PS, EU, China, Russia, Korea, Vietnam); IP issues; China IPR; US-Japan trade forum and reform; KORUS and Korean reform; Taiwan reforms; Turkey GMP inspection requirement; Germany pricing reform, Poland market access, Greece pricing reform, Italy market access
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2010 · second_quarter · Q2
Counterfeit medicines
Patent Reform Ace (S 515); Russian data exclusitivity; Saudi Zyprexa Patent nullification; Russia DE Enactment, Manager's Amendment to S 515; Counterfeit medicines
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2009 · fourth_quarter · Q4
Intellectual Property (IP) issues related to China, ASEAN countries, and India; IPR and Ambassadorial nominations for the UN; S. 242; Canada IP; Mexico IP; Brazil IP; Algeria IP; Egypt IP; Saudi Arabia IP; Peru IP/FTA implementation; Ecuador IP; Argentina IP; Chili IP; Columbia IP; Russia IP/WTO Accession; Turkey IP; Finland IP; Norway IP; Slovenia IP; Sweden IP
Anti-counterfeiting; Anti-counterfeiting Trade Agreement (ACTA); Ambassadorial nominations for the UN, US_ASEAN Summit; Canada S. 242 and intellectual property (IP); Mexico IP; Peru FTA; Columbia FTA; Algeria access; UK pricing; Germany HC reform; Saudi Arabia access/IP; Cuba sanctions; Argentina access and IP; Poland WTO; Russia WTO; Turkey access; Brazil trade negotiations; Japan pricing and regulatory reform; China IPR; Korea pricing reform and FTA; Taiwan pricing reform; Agriculture Appropriations/Trade Provisions (HR 2997)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2009 · second_quarter · Q2
Japan Regulatory reform, Patient Safety/Anti-Counterfeiting
Follow-on biologics (HR 1548, HR 1427, S 726), Patent Reform (HR 1260, S 515, S 615), China IPR, Thailand IPR, Global Intellectual Property Rights and Anti-Counterfeiting
Japan Pricing Reform, Korea Pricing reform, Indonesia Investment Decree, Philippines Pricing Reform, Taiwan TIFA and Pricing Reform, General Trade Policy, Anti-Counterfeiting Trade Agreement (ACTA), Anti-Counterfeiting and IPR in Trade Agreements, Special 301 Report
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2009 · first_quarter · Q1
Veterinary Medicine Market Access; Czech Republic (market access & pricing reform); European Union (Pharmaceutical Package legislation); Finland (IP); Germany (pricing & health care reform); Italy (pricing & health care reform); Norway (IP & market access); Poland (market access); Slovakia (IP & market access); Sweden (pricing & health care reform); United Kingdon (pricing & health care reform); Anti-Counterfeiting Trade Agreement; Latin America Free Trade Agreements; (CONTINUED ON NEXT PAGE) Canada (Pharmaceutical Market Access and Drug Safety Act - S 242 & access restrictions & IP); Cuba (omnibus bill & sanctions); Mexico (IP & market access); Brazil (IP & market access); Algeria (IP & access restrictions); Tunisia (IP & access restrictions); Egypt (IP); Saudia Arabia (IP & access restrictions); Peru (FTA Implementation); Argentina (IP & access restrictions); Chili (IP); Turkey (IP & access restrictions); Russia (IP & WTO accession); Israel (IP); Columbia (IP); South Africa (access restrictions); Japan (pricing & regulatory reform); China (anti-counterfeiting & pricing reform); Taiwan (pricing reform & IP); Korea (pricing reform); Thailand (CL); Indonesia (investment decree); Philippines (pricing reform);
Anti-counterfeiting and patient safety; Anti-counterfeiting Trade Agreement (ACT); US-ASEAN Summit; S 242; Peru counterfeits; Netherland counterfeits; UK counterfeits/Parallel trade; France counterfeits/Parallel trade; EU Parallel trade; Germany Parallel trade; Algeria intellectual property; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
China Counterfeiting and Regulatory, Global Anti-Counterfeiting, Anti-Counterfeiting Trade Agreement (ACTA)
Patent Reform (S 515 & HR 1260); Finland (IP); Norway (IP & market access); Slovakia (IP & market access); China (counterfeiting); Global Anti-Counterfeiting, Anti-Counterfeiting Trade Agreement; World Health Organization; Canada (IP & market access); Mexico (IP & market access); Brazil (IP & market access); Algeria (IP & market access); Tunisia (IP & market access); Egypt (IP); Saudia Arabia (IP & market access); Argentina (IP & market access); Chili (IP); (CONTINUED NEXT PAGE) Turkey (IP & market access); Russia (IP & WTO accession); Israel (IP); Columbia (IP); China (anti-counterfeiting); Taiwan (IP & pricing reform);
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)